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Study objectives: The study examined the relationship between the circadian rhythm of 6-
sulphatoxymelatonin (aMT6s) and ocular measures of sleepiness and neurobehavioural 
performance in shift workers undergoing a simulated night shift. 
Methods: Twenty-two shift workers (mean age = 33.4, SD = 11.8 years) were tested at 
approximately the beginning (2000 h) and the end (0555 h) of a simulated night shift in the 
laboratory. At the time point corresponding to the end of the simulated shift, 14 participants 
were classified as being within range of 6-sulphatoxymelatonin (aMT6s) acrophase - defined 
as three hours before or after aMT6s peak - and eight were classified as outside aMT6s 
acrophase range. Participants completed the Karolinska Sleepiness Scale (KSS) and the 
auditory psychomotor vigilance task (aPVT). Waking electroencephalography (EEG) was 
recorded and infrared reflectance oculography was used to collect ocular measures of 
sleepiness; positive and negative amplitude/velocity ratio (PosAVR, NegAVR), mean blink 
total duration (BTD), the percentage of eye closure (%TEC), and a composite score of 
sleepiness levels (Johns Drowsiness Scale; JDS).  
Results: Participants who were tested within aMT6s acrophase range displayed higher levels 
of sleepiness on ocular measures (%TEC, BTD, PosAVR, JDS), objective sleepiness (EEG 
delta power frequency band), subjective ratings of sleepiness, and neurobehavioural 
performance, compared to those who were outside aMT6s acrophase range.  
Conclusions: The study demonstrated that objective ocular measures of sleepiness are 
sensitive to circadian rhythm misalignment in shift workers. 
Key words: Oculometrics, circadian misalignment, shift work, performance, sleepiness 
Study Rationale: The research was conducted to examine the relationship between circadian 
phase and ocular measures of sleepiness and neurobehavioural performance in a sample of 
shift workers. 
Study Impact: The research demonstrates that ocular measures of sleepiness are 
significantly elevated when shift workers are tested near the peak of the urinary melatonin 
metabolite (6-sulphatoxymelatonin; aMT6s) rhythm, compared to when tested outside the 
aMT6s peak range. These findings suggest that ocular measures of sleepiness may support 




Shift work has become a ubiquitous part of labour practices due to the increasing pressure for 
24-hour provision of goods and services. This drive for round-the-clock productivity, 
however, has resulted in negative consequences to health, safety, and performance1. Such 
consequences have been well-documented in a number of occupational sectors in which peak 
functioning during the night shift is critical, for example commercial transport, mining, 
emergency services and health-care 2. 
The impairment to alertness that occurs during night shift work is mainly attributed to 
misalignment of the imposed sleep-wake cycle from the internally-generated circadian (~24-
hour) rhythm of sleepiness 3, often against a background of chronic sleep deficiency and 
prolonged periods of wakefulness. Alertness and neurobehavioural performance peak when 
the circadian pacemaker promotes wakefulness during the daytime, and decline markedly 
during the night, particularly between 0300h and 0600 h 4, as the circadian pacemaker 
strongly promotes sleep 5. The deleterious effect of the circadian peak in sleep propensity 
occurring during the night shift is further exacerbated by accumulated (homeostatic) sleep 
pressure that results from poor sleep quality and inadequate sleep duration. These are caused 
by the sleep episode occurring at an inappropriate circadian phase 6, and can often prolong 
the duration of the wake episode. The interaction between circadian and homeostatic factors, 
particularly at the end of a night shift, amplifies the risk of accidents and injuries 7. Increased 
sleepiness at the end of a night shift, and the consequent increase in attentional lapses and 
likelihood of falling asleep 8, is a major risk factor for motor vehicle crashes 8, 9. The risk of 
motor vehicle crash is substantially elevated between 2am to 7am  9. 
Sleepiness monitoring systems are often recommended as a component of 
comprehensive Fatigue Risk Management Systems10, although validation studies are limited. 
The most common technologies assessing sleepiness in real-time utilise ocular metrics. 
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Recent studies have assessed the efficacy of ocular metrics as practical tools in providing 
accurate, real-time, continuous assessment of alertness level 11, 12. Ocular measures, such as 
blink durations, are associated with the onset of sleep or microsleeps, and are observed in 
sleep-deprived individuals 13. Such blinks exhibit unique properties, including slowing of the 
closing and reopening phases of a blink, which reflect the sleep/wake-related changes by the 
central nervous system (CNS) 13. These ocular parameters have also been found to be 
sensitive to variations in circadian phase and increased homeostatic sleepiness over time 11, 
suggesting potential utility as a real-time sleepiness monitoring system in occupational and 
on-road settings. Hence, the current study employed the use of an ocular-based sleepiness 
detection system (Optalert™) to assess sleepiness levels in a shift working population during 
a simulated night shift, following a series of night shifts worked in the ‘real-world’. The 
study aimed to examine the relationship between ocular measures of sleepiness and circadian 
phase in shift workers. Specifically, sleepiness and neurobehavioural performance were 
examined in those who were within range of the acrophase of the urinary metabolite of 
melatonin 6-sulphatoxymelatonin (aMT6s) at the end of the simulated night shift, compared 




Materials and methods 
Ethical approval 
The study was approved by the Monash University Human Research Ethics Committee. All 
participants provided written informed consent. The data presented are part of a larger, multi-
centre study examining the effects of a novel light intervention on alertness and 
neurobehavioral performance in night shift workers. 
Participants and pre-study conditions 
A total of 27 healthy shift workers (9M, 18F) aged 31.8 ± 11.2 years (mean ± SD, range 18 – 
64) completed the study at the Monash University Sleep and Circadian Medicine Laboratory. 
Participants were required to be regular night shift workers, working at least five night shifts 
per month including at least two consecutive night shifts. Night shifts were defined as shifts 
with at least six hours on duty between 2200 and 0800 h, and with a maximum scheduled 
shift length of 12 hours. All participants were initially screened for use of medications or 
drugs of abuse, and any history of medical or psychiatric disorders. Participants were 
screened for sleep apnea using the Berlin Questionnaire14 and the Multivariate Apnea 
Prediction (MAP) Questionnaire15. Participants were deemed as high risk of sleep apnea if 
they screened positive on ≥ 2 categories on the Berlin Questionnaire and positive on the MAP 
Apnea Index. Participants were ineligible if they reported transmeridian travel in the past 
month. Participants completed a number of subjective questionnaires including the Epworth 
Sleepiness Scale (ESS) 16; Pittsburgh Sleep Quality Index (PSQI) 17; and the 
Morningness/Eveningness Questionnaire (MEQ) 18. The laboratory-controlled simulated 
night shift was scheduled immediately following a sequence of at least two consecutive night 
shifts of each individual’s normal shift work schedule.  
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For one to three weeks before entering the laboratory for the simulated night shift, 
participants completed a daily sleep/work hours log and wore a wrist actigraphy device 
(Actiwatch-L, Mini-mitter, Inc., Bend, OR). Sleep diary data were used to define the time in 
bed interval for actigraphic sleep analysis, whereby, if self-reported bed time was 30 minutes 
or more prior to or post a sustained substantial reduction in activity, then bed time was 
modified to the start of the sustained substantial reduction in activity; if self-reported wake 
time was 30 minutes or more prior to or post a sustained substantial increase in activity, then 
wake time was modified to the start of the sustained substantial increase in activity. 
Participants were asked to refrain from use of any prescription or non-prescription 
medications throughout the pre-study monitoring and simulated shift, and abstain from any 
recreational drugs for at least a month prior to the study. Participants were also required to 
abstain from alcohol for at least 24 hours, and abstain from caffeine and nicotine for 12 
hours, prior to sleep laboratory entry. Compliance was verified by urine toxicology upon 
admission to the laboratory. 
For 48 h prior to the beginning of the simulated night-shift, participants collected 
approximately four-hourly sequential urine samples (eight-hourly during sleep episodes) for 
measurement of the major urinary metabolite of melatonin, 6-sulphatoxymelatonin (aMT6s). 
The final urine sample was taken in the laboratory at the beginning of the simulated night 
shift. After each collection, participants recorded the volume of the sample and the time of 
urine collection. A 5-mL urine aliquot was frozen (-20°C) and subsequently analysed by 
aMT6s radioimmunoassay 19 at the Adelaide Research Assay Facility, University of Adelaide 
using reagents purchased from Stockgrand, Ltd., University of Surrey (Guildford, UK). The 
aMT6s intra-assay Coefficient of Variation (CV) was 7.2% and the inter-assay CVs were 
23%, 7% and 11% at 3.6 ng/ml, 15.6 ng/ml and 29.6 ng/ml, respectively. The minimum 
detectable concentration was 0.5 ng/ml. Participants were asked to continue their own 
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schedule in the 48 hours prior to the shift, and no instructions were given to restrict light 
exposure. 
Shift work occupation categories 20 were as follows; Health Professionals (n=7, 26%); 
Machine and Stationary Plant Operators (4, 18%); Hospitality workers (3, 11%); Hospitality, 
Retail and Service Managers (3, 11%); Business, Human Resource and Marketing 
Professionals (2, 9%); Other (5, 18%); and three (14%) participants’ occupations were 
unknown.  
Simulated night-shift protocol 
The simulated night shift occurred in a sleep laboratory free of time cues: participants had no 
access to windows, clocks, television, radio, internet, or telephone, and were continually 
supervised by trained staff. Participants were instructed to arrive at the laboratory at 1730 h. 
Testing began at 1900 h and ended at 0815 h the following day and participants were required 
to remain awake while supervised. Between 1900 h and 2300 h, and from 0700 to 0815 h, 
participants were exposed to standard room lighting at eye level (vertical plane). Between 
2300 h and 0700 h, participants were randomly allocated to one of two fluorescent lighting 
conditions: 4,000 K or 17,000 K (Philips Bright Light Devices, HF3305, The Netherlands). 
Lighting illuminance levels were maintained between 100 to 150 lux across the simulated 
shift. Only data collected from the 4,000 K light group are reported herein. 
For the duration of the simulated shift participants were asked to remain seated in the 
centre of the room in front of a computer which was used to administer each test battery, 
except for scheduled brief toilet breaks provided every two hours. Participants completed 
hourly cognitive test batteries from 1900 h to 0100 h, a test at 0300 h, and then hourly tests 
from 0500 h to 0800 h. In between test batteries participants were permitted to read or watch 
selected movies.  
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Data presented here were collected during the beginning (2000 h) and end (0555 h) of 
the simulated night shift. 
Infrared Oculography 
Participants’ eye and eyelid movements were monitored by infrared reflectance (IR) 
oculography (Optalert™ 21) to record drowsiness levels continuously during the simulated 
night shift. IR transducers fitted to spectacle frames were positioned towards the top eye lid 
to measure the relative velocity of the opening and closing phase of the eye lid, and duration 
of each blink. Optalert™ glasses can be worn with contact lenses, and also support 
prescription spectacles. However, none of the participants in our study required prescription 
lenses. The system provides thirteen ocular measures sampled each minute, of which the 
following were selected based on previous work 21-27 (detailed description of each measure 
provided in Table 1): positive and negative amplitude/velocity ratio of each blink (PosAVR, 
NegAVR); Johns Drowsiness Scale (JDS) score; the percentage of time with eyes closed 
(%TEC); and mean blink total durations (BTD). For all measures, higher values indicate 
higher levels of sleepiness. The commercially available system is designed to emit auditory 
warnings; however, these warnings were disabled in the present research study, such that the 
system was used purely to monitor alertness state. 
Sleepiness and Performance Assessments 
Subjective sleepiness was rated using the Karolinska Sleepiness Scale (KSS; 9-point scale 
from 1-“very alert” to 9-“very sleepy, fighting sleep”) 28 by pressing the appropriate number 
on a computer keyboard when prompted. 
Sustained attention was assessed using a 10-minute auditory psychomotor vigilance 
task (aPVT) 29, 30. An auditory stimulus was presented at random intervals (1-9 seconds); the 
participant was asked to respond to the sound by pressing a button as quickly as possible. No 
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simultaneous visual stimulus was presented. The auditory version of the PVT was used as it 
was more appropriate for administration during a period of light exposure within the larger 
protocol (data not included here), and to maintain consistency with our previous studies 12. 
The aPVT is a validated measure of sustained attention and a reliable index of objective 
sleepiness30, 31, and correlates with visual PVT during sleep deprivation30. 
Waking EEG Recordings  
EEG and electro-oculogram (EOG) recordings were made continuously throughout the 
simulated night shift using a portable, wireless, ambulatory, polysomnographic recorder 
(Siesta, Compumedics Ltd., Victoria, Australia). EEG electrodes were positioned according 
to the International 10/20 System and recorded at eight sites (F3, F4, C3, C4, P3, P4, O1 and 
O2) against a Cz reference and subsequently digitally re-referenced to linked mastoids (M1 
and M2). Only data from C3 are reported here. EOG was recorded with electrodes placed 2 
cm above and below lateral canthus of the left and right eye, respectively. EEG and EOG data 
were sampled at 512 Hz and electrode impedances were < 10 kΩ. Raw EEG time series were 
imported as European Data Format (EDF) files into Curry 7 software (Compumedics 
Neuroscan, Victoria, Australia) and were digitally band-pass filtered (0.3 – 30 Hz, 24 
dB/octave). EEG data were sampled during the 3-minute Karolinska Drowsiness Test (KDT) 
28, during which participants were instructed to fixate on a 5 cm black dot on a computer 





Cosinor analysis of aMT6s values were used to determine acrophase time or peak of aMT6s 
32. Participants were classified into groups based on whether or not they were within range of 
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the aMT6s acrophase, which coincides approximately with the peak in the circadian rhythm 
of sleep propensity 33. The range of aMT6s acrophase was defined based on a review by 
Arendt 34 describing the biological night as the hours between aMT6s onset and offset and 
refined based on Lockley, Skene, Arendt, Tabandeh, Bird and Defrance 35, who reported the 
mean and 2-SD range of normal aMT6s acrophases as 4.2 ± 2.9 h. Therefore, in the current 
study, participants were classified as being within aMT6s acrophase range if the final testing 
session (0555 h) occurred ± 3 hours from the time of their aMT6s acrophase as measured in 
the 24 hours prior to entering the laboratory. The conservative estimate used here is aimed at 
isolating the six hour time interval in which sleepiness is expected to be highest. 
For aPVT measures, reaction times less than 100 ms and >10,000 ms were excluded 
as false starts and distractions, respectively30, 36. Mean aPVT reaction time (RT) and number 
of lapses (responses >500ms) for each 10-minute test were calculated. aPVT RT scores were 
transformed with an inverse (1/RT) function, and square root was applied to aPVT lapses 37. 
Ten minute recordings of each ocular measure were extracted coincident with the 10-
minute aPVT. Ocular measures recorded during aPVT were selected for analysis to reduce 
variance across participants as they were instructed to remain still with eyes directed at the 
screen ahead and concentrate on the task. Ocular measures recorded during the KDT could 
not be used in the analysis as participants were instructed to blink as little as possible during 
the three minute task. As ocular measures are derived from eye blinks, ocular measures 
recorded during this task may be an inaccurate representation of the participants’ sleepiness 
level. Ocular data were cleaned based on signal quality 11; data were retained when more than 
50% of each one minute epoch displayed a clear blink signal.  
Waking EEG signals were derived from C3 referenced to linked mastoids during each 
KDT. ECG artefact were removed using subtraction of a single component derived from a 
Principle Components Analysis of an average ECG artefact across all electrodes. Two-second 
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epochs containing muscle or eye blink artefacts were discarded from further analysis (<5% of 
all epochs). Artefact-free two-second epochs were subjected to off-line spectral analysis 
using a fast-Fourier transformation and a 5% hanning window (Curry 7 software, 
Compumedics Neuroscan, Victoria, Australia). Power spectral data were analysed between 
0.5 and 30 Hz to remove any high and low frequency artefacts with outliers greater/less than 
two standard deviations from the mean being removed. EEG power values were summed 
across consecutive frequency bins (0.5 Hz resolution) within four frequency bands (delta 
[0.5–4.0 Hz], theta [4.1–8.0 Hz], alpha [8.1–12.0 Hz], and beta [14.1–30 Hz]). Summed 
frequency band values were then averaged across 2 second epochs within each KDT for final 
analysis. 
IBM SPSS Statistics 20.0 (IBM Corp., Somers, NY, USA) was used for statistical 
analysis. A mixed design ANCOVA was conducted to assess the interaction of circadian 
group (participants ± 3 hours of aMT6s acrophase range and those who were tested outside 
aMT6s acrophase range) across two time points (baseline 2000 h, and end of shift 0555 h) on 
participants’ ocular measures, aPVT performance, subjective sleepiness, and EEG. 
Participants’ age, body mass index (BMI), and time in bed (TIB) in the 24 hours prior to the 
simulated shift were used as a priori covariates in the analysis: age-related changes in the 
timing of circadian drive have been found 38; BMI increases the risk of obstructive sleep 
apnea 39; and time in bed in the past 24 hours was included to control for variation in 
homeostatic sleep pressure while assessing differences in circadian phase. To confirm that the 
assumption of equal variance was not violated, Levene’s test for Equality of Variances was 






Five out of 27 participants had poor quality aMT6s rhythm as determined by cosinor analysis 
of the 24-hour rhythms across the 48-hour collection period, and visual inspection of the 
consistency in the pattern of the 24 hour rhythm; data were consequently excluded from 
analyses. The remaining 22 participants exhibited a significant cosinor fit (α set 0.1040; 91% 
were p<0.05). As expected, no participants were within aMT6s acrophase range at the 
baseline testing session (see Figure 1). The end-shift testing session occurred ± 3 hours of 
aMT6s acrophase for 14/22 participants (hours relative to aMT6s acrophase: mean = 0.17 ± 
SD 0.59 h; range = -2.83 to 2.73 h), while eight participants were tested outside of this range 





Of the 22 participants with aMT6s data, one had insufficient ocular data at the 
baseline test due to poor signal quality and the 2100 h test was subsequently substituted as the 
baseline. Three additional participants had missing ocular data at the 0555 h scheduled test 
and therefore data from the 0500 test were substituted. A further six participants were 
excluded from ocular analyses; one participant had a weak signal throughout testing and, as a 
result, an insufficient amount of blinks were recorded; two participants did not have sufficient 
baseline ocular data for comparison; and three participants had a large amount of noise at all 
time points causing blinks to be unclear and data unreliable. A total of 16 participants were 
therefore included in the ocular analyses (within aMT6s acrophase range, n = 9; outside 
aMT6s acrophase range, n = 7).  
One participant did not have EEG recorded during the 2000 h scheduled test; EEG 
data during the next KDT (2100 h) test was substituted as the baseline time point for all 
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measures. One participant did not have sufficient EEG data collected throughout simulated 
shift KDTs and thus excluded from EEG analyses.  
Overall, data during the baseline test occurred at a mean time of 2012 h (SD ± 0018 
h), while the mean end-of-shift test occurred at 0550 h (SD ± 0019 h). Participants’ work 
shifts prior to the simulated shift started on average at 2103 h (SD ± 0150 h) and ended at 





Ocular measures and sleepiness 
All ocular measures (%TEC, BTD, PosAVR, JDS), except NegAVR, displayed a significant 
time by circadian group interaction (see Table 3). At the completion of the simulated shift, 
the mean %TEC values of participants ± 3 hours of  aMT6s acrophase range increased more 
than 10-fold from 0.73 % (SD±1.0) to 8.01% (±1.8) (Figure 2; See Supplementary Online 
Material [SOM] Figure S1), whereas participants outside aMT6s acrophase range had only a 
minor increase from baseline to the end-of-shift (F1,11=6.00, p = .032). JDS scores of 
participants ± 3 hours of  aMT6s acrophase range significantly increased to nearly double 
their baseline value, from 2.5 (±0.7) to 4.9 (±0.6), at the end-of-shift in comparison to 
baseline, while participants outside  aMT6s acrophase range displayed only a slight increase 
across time points (F1,11=7.50, p = .019). A similar result was observed in BTD between the 
two groups (F1,11=9.86, p = .009). A significant increase in PosAVR values from baseline 
levels was also observed in participants ± 3 hours of aMT6s acrophase range (F1,11=20.36, p 












Performance and subjective sleepiness  
KSS displayed a significant time by circadian group interaction (F1,17=14.74, p = .001; Figure 
3). Mean subjective sleepiness scores of participants ± 3 hours of aMT6s acrophase range 
increased from 4.3 (SD ± 0.6) to 7.6 (± 0.5) across the simulated shift, while subjective 
sleepiness of participants who were outside aMT6s acrophase range decreased marginally at 
the end of the shift from 5.2 (± 0.8) to 5.0 (± 0.7). 
 Similar results were observed in the aPVT RT scores, which showed a significant 
time by circadian group interaction (F1,17=7.86, p = .012; Figure 3; See [SOM] Figure S1). 
RT scores decreased over time in participants tested outside the aMT6s acrophase range, 
while RT scores increased at the end of the simulated shift for participants who were tested 




EEG assessment of alertness  
Significant interaction of time and circadian group was detected only in the EEG delta 
frequency band (0.5–4.0 Hz) (F1,13=4.77, p = .048). Participants within aMT6s acrophase 
range showed an increase in the delta frequency from baseline to the end-of-shift test, 








This study demonstrated that ocular measures of sleepiness (%TEC, BTD, PosAVR, JDS) 
show predictable increases across a simulated night shift when shift workers are assessed ± 3 
hours of aMT6s acrophase range, compared to those outside the aMT6s acrophase range. 
Similar results were observed in measures of subjective sleepiness (KSS), objective 
sleepiness (EEG delta activity), and attentional performance (aPVT). 
We observed considerable inter-individual variability in circadian phase, as assessed 
by the timing of the peak in the aMT6s rhythm; the end-of-shift assessment of sleepiness and 
performance occurred at a time ranging from 7.2 h before to 6.0 hours after the aMT6s peak. 
This variability in circadian phase across the simulated night shift may be the result of 
behavioural, biological, and/or environmental influences. Participants had worked a variable 
number of night shifts before entering the laboratory, therefore resulting in variability in 
sleep-wake history and light-dark exposure. We did not, however, observe significant 
differences in shift or sleep-wake history between participants in the two circadian phase 
groups, or between shift workers with an earlier phase (i.e. aMT6s acrophase before end of 
shift test; n = 10) versus those with a later phase (i.e. aMT6s acrophase after end of shift test; 
n = 12; p>0.05), suggesting that these factors are unlikely to account for the observed 
differences in circadian phase. 
Measures of blink duration (BTD), amplitude/velocity ratio (PosAVR), percentage of 
time with eyes closed (%TEC), and a composite measure of these variables (JDS) displayed 
larger increases in sleepiness across the simulated night shift in those who were tested ± 3 
hours of aMT6s acrophase range, compared to those tested outside this range. The increased 
rate of accumulation of sleepiness across the night shift in those tested within aMT6s 
acrophase range likely reflects the interactive effects of circadian and homeostatic influences 
on sleepiness. For example, sleep efficiency was relatively low in our participants, most 
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likely because sleep is scheduled during the daytime when the circadian pacemaker is 
promoting wakefulness41, thus resulting in chronic sleep deficiency. Ocular metrics have 
previously demonstrated their sensitivity to the fluctuations in sleepiness due to homeostatic 
and circadian processes11, 23.  
 
In line with the oculometric measures of sleepiness, subjective sleepiness (KSS), 
neurobehavioural impairment (aPVT), and objective sleepiness (EEG) also increased at the 
end of the simulated night shift in participants ± 3 hours of aMT6s acrophase range. All EEG 
power frequency bands showed a trend towards increasing across the simulated night shift in 
both circadian groups, suggesting overall general accumulation of sleepiness across the shift 
in all shift workers. However, participants who ended their shift within the range of aMT6s 
acrophase displayed significantly higher delta power compared to those who were outside 
aMT6s acrophase range. This suggests a higher sleep propensity when tested around the 
aMT6s peak, over and above the effects of elevated homeostatic sleep pressure caused by 
chronic sleep deficiency and prolonged wakefulness. Similar findings were observed in a 
study by Torsvall and Åkerstedt 42, who assessed subjective and objective sleepiness in night 
working train drivers. The study showed more rapid increase in self-reported sleepiness and 
EEG alpha, theta, and delta activity during the night journey 42. The current study extended 
these findings by showing that working near the aMT6s peak substantially influences the 
degree of sleepiness observed at the end of a night shift. 
 
The findings of the study provide further evidence of the utility of oculometrics as 
objective measures of sleepiness in shift workers. It is acknowledged, however, that the 
assessment of neurobehavioural impairment (aPVT) occurred under controlled laboratory 
conditions and hence the extent to which findings may be extrapolated to field settings is 
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unknown. It should be noted that 18% (5/27) of the initial sample had missing phase data. 
Furthermore, six of the 22 participants with circadian data (59% of the initial sample) had 
ocular data deemed to be of poor quality and were excluded, further limiting the sample size. 
It should be noted, however, that while the collection procedure meant that ocular measures 
were sometimes limited by signal quality, the measures themselves remain sensitive to 
circadian and homeostatic variations in alertness11, 12, 27. Careful consideration should be 
given to how oculometric data are collected in future studies. Nonetheless, several aspects of 
the study were ecologically valid. First, night shift workers were recruited to the study, and 
assessed in this protocol following a sequence of night shifts in the real-world. Second, the 
oculographic system (Optalert™) we utilised is marketed and increasingly used as a 
technology to support fatigue risk management in occupational settings. A major limitation in 
the assessment of driver sleepiness is the lack of widely-accepted, real-time methods. 
Measures that rely on offline processing or repeated neurocognitive testing are not practical 
in this context. While subjective assessments of sleepiness have been found to be accurate in 
the laboratory, their relationship to objective sleepiness measures has not been shown reliably 
in applied settings 43, 44. Hence self-ratings of sleepiness have limited value in the workplace 
compared to objective sleepiness measures, which do not rely upon the accuracy of an 
individual’s introspection. In-vehicle sleepiness-detection systems provide the driver with 
immediate notification of their current alertness state and risk of performance impairment and 
attentional failure in the future, potentially preventing sleepiness-related motor vehicle 
crashes. The present study adds to the growing literature showing the utility of oculometrics 
in sleepiness measurement technologies, specifically by showing the sensitivity of these 




aMT6s profiles in the field may be impacted by light suppression of melatonin 
synthesis. While this may be a potential limitation to the research, the method is well-
established in the literature as a suitable real-world assessment of circadian phase, of which 
the techniques and protocols used here have been applied successfully in several prior studies 
of shift workers on North Sea oil rigs 45-49, in shift working nurses 50-52, in shift workers living 
in Antarctica 53, 54, and in many clinical populations and experimental protocols (e.g. 35, 55-58). 
To assess the potential impact of light on aMT6s, in a previous study we compared aMT6s 
with urinary cortisol (which is much less confounded by light) in a subset of sighted 
individuals (n=7) and found a strong relationship between the phase estimates (average 
Pearson r ± SD, 0.98 ± 0.01, p<0.05)40. The study is limited by the short time lag between the 
estimation of phase and performance assessment in the laboratory (up to 24 hours).  
The findings of the study highlight the importance of effective alertness management 
strategies during the night shift work and the drive home at around the circadian nadir. 
Assessing whether or not an individual is working near the circadian peak during a night shift 
appears to be an important component of safety risk management. Crowley, Lee, Tseng, Fogg 
and Eastman 59 found that performance, sleepiness, and mood are improved in participants 
who show circadian entrainment to a simulated night shift, compared to those who do not 
show entrainment, and thus are working at an adverse circadian phase. The authors reported 
significant associations between the magnitude of circadian entrainment and performance 
levels59. The current study supports the findings of Crowley and colleagues, and further 
demonstrates that in a sample of shift workers performing a simulated night shift after a 
series of night shifts in their normal environment, performance is impaired and sleepiness 




While the study used a relatively small sample, and thus limiting statistical power and 
the ability to generalise across the population, the study conducted in a sample of actual shift 
workers contributes to the body of knowledge examining the consequences of working near 
the aMT6s acrophase. Targeted interventions are warranted to manage the negative impact on 
occupational safety and performance due to circadian disruption, and the consequential sleep 
deficiency, associated with shift work 1, 7. The mismatch between the circadian pacemaker, 
the sleep-wake cycle, and environmental cues has been found to have serious impacts on 
performance and safety 2 particularly when there is a need to perform during the biological 
night. Future studies assessing ocular measures of sleepiness should investigate inter- and 
intra-individual variation in these measures, to provide greater insight into their utility and 
validity. 
 
In conclusion, shift workers who are working within range of the aMT6s acrophase 
display increased sleepiness and performance impairment during a simulated night shift. The 
study is the first to demonstrate sleepiness-related ocular responses to the circadian nadir of 
alertness in a sample of shift workers, and contributes to the ongoing effort to develop real-
time sleepiness measures as a part of occupational risk management systems.  
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Figure 1. Relationships between testing times and circadian phase in each participant. 
Melatonin urinary metabolite aMT6s acrophase of each participant (open diamond symbols) 
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overlayed with start of shift baseline test times (open circle symbols), and end of shift test 
time: those tested outside aMT6s acrophase range (open square symbols) and those tested ± 3 
hours of aMT6s acrophase range (closed square symbols). Note: error bars displayed 
represent ±3 hours from the time of aMT6s acrophase, which according to previous work34, 
35, is the expected time of the circadian nadir of alertness.  
 
Figure 2. Ocular measures assessed across a simulated night shift, between circadian 
groups. Circadian group was categorised based on whether each participant was tested ± 3 
hours of the melatonin urinary metabolite (aMT6s) acrophase. A: Mean scores at baseline 
2000 h time point, and end of simulated shift time point 0555 h. B: Mean change from 
baseline scores. Asterisks indicate significant interaction (p < 0.05). Error bars represent 
standard deviation. JDS, Johns Drowsiness Scale; PosAVR; positive amplitude/velocity ratio; 
TEC%, percentage of time with eyes closed; NegAVR, negative amplitude/velocity ratio; 
BTD, blink total duration.  
 
Figure 3. Self-rated sleepiness and auditory PVT (aPVT) assessed across simulated 
night shift, between circadian groups. Circadian group was categorised based on whether 
each participant was tested ± 3 hours of the melatonin urinary metabolite (aMT6s) acrophase. 
A: Mean scores at baseline 2000 h time point, and end of simulated shift time point 0555 h. 
B: Mean change from baseline scores. Error bars represent standard deviation. Asterisks 
indicate significant interaction (p < 0.05). KSS, Karolinska Sleepiness Score; aPVT, auditory 




Figure 4. Change EEG power from baseline test to end of shift test between circadian 
groups. Circadian group was categorised based on whether each participant was tested ± 3 
hours of the melatonin urinary metabolite (aMT6s) acrophase (Mean ± SD). EEG was 
grouped into the following frequency bands: delta (0.5–4.0 Hz), theta (4.1–8.0 Hz), alpha 
(8.1–12.0 Hz), and beta (14.1–30 Hz). Asterisks indicate significant interaction (p < 0.05). 





Table 1. Ocular measures derived from Optalert™ sleepiness technology 
Johns Drowsiness Scale Score (JDS) 
 
JDS is a composite score of ocular measures used to calculate an individual’s level of 
sleepiness in real time, providing a minute-to-minute Johns Drowsiness Scale (JDS) rating 
(see Johns et al.21). JDS is a continuous scale with scores ranging from 0 to 10 (very alert 
to very drowsy, respectively). The commercially-available system is designed to emit 
auditory warnings when individuals reach a JDS score of 4.5 to 4.9 (cautionary level of 
sleepiness), and a score of 5.0 or above (critical level of sleepiness), which is associated 
with an increased risk of severe lane excursions on a driving simulator21, 60, 61.  
Positive Amplitude/Velocity Ratio (PosAVR) 
 
Ratio of the maximum amplitude to the maximum velocity of the closing phase of a 
blink21. 
Percentage of time with eyes closed (%TEC) 
 
Percentage of time that the eyes are deemed closed in each minute. The eyes are deemed 
closed when the velocity of the eyelid movement following the closing of the eyelid drops 
below the velocity threshold, and is deemed closed until the velocity increases back above 
this threshold indicating the beginning of the re-opening of the eyelids. 
Negative Amplitude/Velocity Ratio (NegAVR) 
 
Ratio of the maximum amplitude to the maximum velocity of the re-opening phase of a 
blink21. 
Blink total duration (BTD; seconds) 
 
The mean total blink duration of all blinks over the course of 1 min. Total blink duration 





Table 2. Participant descriptives 
 End of shift test ± 3 h of aMT6s 
acrophase   
End of shift test outside ± 3 h of 
aMT6s acrophase  p 
 N % Mean ± SD  N % Mean ± SD  
 Demographics           
 N 14     8     
 Age   32.1 13.5    35.6 8.5 0.52 
 Sex (M, F) 9, 5     6, 2     
 BMI   23.7 3.2    26.9 1.5 0.02 
 Sleep-wake           
 ESS   7.7 4.4    11.4 4.4 0.07 
    ≥ 10 4 28.6    4 50.0    
 PSQI   5.9 2.5    7.4 1.6 0.11 
    ≥ 5 8 57.1    7 87.5    
 MEQ   53.0 8.6    45.1 11.2 0.08 
 Sleep History           
 Wake time (24 hours prior; h)   13:55 01:56    13:46 01:52 0.87 
 TIB 24 h (h)   6.6 1.3    6.3 1.2 0.61 
 Mean TIB 7 days (h)   6.3 1.6    6.7 1.9 0.37 
 Sleep efficiency 24 h (%)   79.5 9.8    82.6 5.0 0.42 
 Mean sleep efficiency 7 days (%)   77.6 7.5    74.4 10.0 0.43 
 Hours awake at baseline (h)   6.3 2.0    6.6 1.8 0.70 
 Work schedule history           
 Mean shift start time (prior to simulated shift; h)   21:10 1:53    20:52 1:51 0.72 
 Mean shift end time (prior to simulated shift; h)   6:05 1:21    6:13 1:13 0.82 
 Number of consecutive night shifts prior   3.3 1.7    4.6 2.2 0.13 
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    Total hours worked   30.7 16.3    44.7 23.6 0.12 
Note: Sleep history was based on sleep logs and verified with actigraphy. No participants napped (<1 hour) in the 24 hours prior to the 
simulated night shift. BMI, Body Mass Index; ESS, Epworth Sleepiness Scale (range 0 – 24; higher scores indicate greater state-sleepiness); 
PSQI, Pittsburgh Sleep Quality Inventory (range 0 – 21; higher scores are indicative of greater sleep difficulty); MEQ, 





Table 3. Table of analyses 
 N Group  Time  Group x Time 
  F df p Partial η2 
 F df p Partial η2 
 F df p Partial η2 
Ocular measures                
 JDS 9, 7 0.66 1,11 .435 .056  0.69 1,11 .424 .059  7.50 1,11 .019 .406 
 PosAVR 9, 7 12.05 1,11 .005 .523  3.36 1,11 .094 .234  20.35 1,11 .001 .649 
 %TEC 9, 7 0.76 1,11 .402 .065  0.01 1,11 .928 .001  6.00 1,11 .032 .353 
 NegAVR 9, 7 0.704 1,11 .419 .060  0.27 1,11 .611 .024  3.01 1,11 .110 .215 
 BTD 9, 7 2.25 1,11 .162 .170  0.31 1,11 .587 .028  9.86 1,11 .009 .437 
 Neurobehavioural performance              
 PVT RT 14, 8 0.014 1,17 .908 .001  0.247 1,17 .625 .014  7.855 1,17 .012 .316 
 PVT Lapses 14, 8 0.344 1,17 .565 .020  0.989 1,17 .334 .055  3.494 1,17 .079 .170 
Subjective Sleepiness               
 KSS 14, 8 0.821 1,17 .378 .046  8.849 1,17 .008 .342  14.741 1,17 .001 .464 
EEG measures                
 Delta power 12, 6 0.366 1,13 .555 .027  1.930 1,13 .188 .129  4.766 1,13 .048 .268 
 Theta power 12, 8 0.073 1,15 .791 .005  0.759 1,15 .397 .048  .059 1,15 .811 .004 
 Alpha power 13, 6 0.008 1,14 .931 .001  0.417 1,14 .529 .029  1.756 1,14 .206 .111 
 Beta power 12, 7 0.141 1,14 .713 .010  1.343 1,14 .266 .088  .209 1,14 .655 .015 
N  = tested within MT6s acrophase range, tested outside aMT6s acrophase range; participants’ age, body mass index (BMI), and time in bed in 
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